Ed Arce Analyst PerformanceSenior Research Analyst, Biotechnology at Westpark CapitalEd Arce is a stock analyst at Westpark Capital focused in the medical sector, covering 38 publicly traded companies. Over the past year, Ed Arce has issued 40 stock ratings, including buy and hold recommendations. While full access to Ed Arce's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Ed Arce's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings120 Last 11 YearsBuy Recommendations93.28% 111 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution119RatingsDistribution of strong buy, buy, hold, and sell ratings by Ed Arce.RatingPercentageCount Strong Buy0.0%0 ratings Buy93.3%111 ratings Hold6.7%8 ratings Sell0.0%0 ratingsOut of 119 total stock ratings issued by Ed Arce at Westpark Capital, the majority (93.3%) have been Buy recommendations, followed by 6.7% Hold.Best & Worst CallsBest Call0000.0%TBRAAug 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CBAYFeb 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.4% of companies on NASDAQ37 companiesOTCMKTS2.6% of companies on OTCMKTS1 companyEd Arce, an analyst at Westpark Capital, currently covers 38 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical35 companies92.1%Miscellaneous3 companies7.9%Ed Arce of Westpark Capital specializes in stock coverage within the Medical sector, with additional focus on companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE14 companies36.8%MED - DRUGS9 companies23.7%PHARMACEUTICAL PREPARATIONS9 companies23.7%Miscellaneous3 companies7.9%BIOTECHNOLOGY2 companies5.3%MED - GENERIC DRG1 company2.6% About Ed ArceEd Arce joined WestPark Capital as a Managing Director to build a leading healthcare research platform. Mr. Arce covers emerging and small-to-midcap (SMID) biotechnology companies, focused on several therapeutic areas including hepatology; cardiovascular, renal & metabolism (CRM); inflammation & immunology (I&I); gastroenterology; and rare diseases. Mr. Arce brings nearly 20 years of experience with prior appointments at H.C. Wainwright, Roth Capital Partners, MLV & Co., Wedbush Securities and UBS Securities. In 2017, Mr. Arce was awarded the No. 1 Stock Picker in Biotechnology in the United States by the Thomson Reuters Analyst Awards. Mr. Arce holds a B.S. in Civil Engineering and an MBA from Florida International University, an M.S. in Finance from Boston College, and an Executive Education Certificate by completing the Chief Financial Officer (CFO) Program from Columbia University. Mr. Arce holds the Series 7, 63, 86, and 87 registrations. Ed Arce's Ratings History at Westpark Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsENTAEnanta Pharmaceuticals9/30/2025Boost Price Target$15.16$28.00Buy$0.0000.00% ROIENTAEnanta Pharmaceuticals9/2/2025Initiated Coverage$8.40$24.00Buy$0.0000.00% ROITVTXTravere Therapeutics6/11/2025Upgrade$15.13$30.00Buy$0.0000.00% ROIUNCYUnicycive Therapeutics4/11/2025Reiterated Rating$5.30$75.00Buy$0.0000.00% ROIARCTArcturus Therapeutics4/10/2025Reiterated Rating$8.86$60.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics4/4/2025Reiterated Rating$1.88$7.50Buy$0.0000.00% ROIUNCYUnicycive Therapeutics4/1/2025Boost Price Target$5.75$75.00Buy$0.0000.00% ROITLPHTalphera4/1/2025Reiterated Rating$0.50$6.00Buy$0.0000.00% ROIALGSAligos Therapeutics3/31/2025Reiterated Rating$9.12$70.00Buy$0.0000.00% ROIIVAInventiva3/28/2025Reiterated Rating$2.94$13.00Buy$0.0000.00% ROIDRRXDURECT3/27/2025Reiterated Rating$0.80Neutral$0.0000.00% ROIASMBAssembly Biosciences3/24/2025Reiterated Rating$11.01Neutral$0.0000.00% ROIACXPAcurx Pharmaceuticals3/19/2025Reiterated Rating$8.36$240.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics3/14/2025Reiterated Rating$1.69$7.50Buy$0.0000.00% ROIALGSAligos Therapeutics3/11/2025Lower Price Target$10.41$70.00Buy$0.0000.00% ROISGMTSagimet Biosciences3/11/2025Reiterated Rating$3.33$32.00Buy$0.0000.00% ROICDTXCidara Therapeutics3/10/2025Boost Price Target$23.66$35.00Buy$0.0000.00% ROIARCTArcturus Therapeutics3/7/2025Lower Price Target$14.31$60.00Buy$0.0000.00% ROIAKROAkero Therapeutics3/3/2025Boost Price Target$49.12$75.00Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals2/28/2025Boost Price Target$46.97$72.00Buy$0.0000.00% ROIETNB89BIO2/28/2025Reiterated Rating$9.06$21.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals2/27/2025Boost Price Target$355.88$405.00Buy$0.0000.00% ROIRAREUltragenyx Pharmaceutical2/14/2025Reiterated Rating$43.52$95.00Buy$0.0000.00% ROIARCTArcturus Therapeutics2/14/2025Reiterated Rating$17.79$63.00Buy$0.0000.00% ROIENTAEnanta Pharmaceuticals2/11/2025Reiterated Rating$4.90$18.00Buy$0.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79Neutral$0.0000.00% ROIGNFTGENFIT2/7/2025Reiterated Rating$3.99$13.00Buy$0.0000.00% ROIIVAInventiva1/30/2025Reiterated Rating$2.53$13.00Buy$0.0000.00% ROIUNCYUnicycive Therapeutics1/29/2025Reiterated Rating$5.39$40.00Buy$0.0000.00% ROIAKROAkero Therapeutics1/27/2025Boost Price Target$51.68$72.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics1/23/2025Reiterated Rating$2.32$7.50Buy$0.0000.00% ROIETNB89BIO1/21/2025Reiterated Rating$6.31$29.00Buy$0.0000.00% ROIABUSArbutus Biopharma1/21/2025Reiterated Rating$3.20$5.00Buy$0.0000.00% ROITLPHTalphera1/21/2025Reiterated Rating$0.67$6.00Buy$0.0000.00% ROIAKROAkero Therapeutics1/16/2025Reiterated Rating$22.45$50.00Buy$0.0000.00% ROITVTXTravere Therapeutics1/15/2025Boost Price Target$17.07$22.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics1/14/2025Reiterated Rating$1.88$7.50Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals1/14/2025Boost Price Target$303.70$400.00Buy$0.0000.00% ROIARCTArcturus Therapeutics1/13/2025Reiterated Rating$16.63$63.00Buy$0.0000.00% ROIACXPAcurx Pharmaceuticals1/10/2025Reiterated Rating$15.54$240.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
